The principal aim of our study was to evaluate the impact of anti-HBc seropositivity on the sustained virological response rates in treatment-naïve chronic hepatitis C patients with high pretreatment viral load, treated with PEG-IFNa2b plus RIB under real life conditions in Greece. This evidence concerns the gene KRT88P and chronic hepatitis C virus infection.